Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873362 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
A Phase 3 study of Breast Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,188
- Enrollment target
- 20
- Study locations
NCT04873362 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,188 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04873362, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Placebo
- DRUG Atezolizumab
- DRUG Trastuzumab Emtansine
Study Locations (20)
Virginia
- Hematology Oncology Associates of Fredericksburg, Inc. - Fredericksburg
- Virginia Oncology Associates - New Port News - Newport News
- Virginia Oncology Associates - Norfolk
- Virginia Cancer Institute - Richmond
- Virginia Oncology Associates - Virginia Beach - Virginia Beach
California
- Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center - Buena
- UCLA Medical Center - Santa Monica
- Innovation Clinical Research Institute - Whittier
Tennessee
- The West Clinic - Germantown
- Thompson Cancer Survival Center - Knoxville
Alabama
- Alabama Oncology - Birmingham
Florida
- Florida Cancer Specialists - West Palm Beach
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Carrollton
Iowa
- University of Iowa - Iowa City
Maine
- New England Cancer Specialists - Westbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,188 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2034-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04873362
The ClinicalTrials.gov registry entry for NCT04873362 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.
NCT04873362 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Virginia, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04873362 about?
NCT04873362 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy". This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in th...
What is the current status of trial NCT04873362?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,188 participants. The study started on 2021-05-04. Estimated completion is 2034-10-02.
What conditions does trial NCT04873362 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04873362?
The interventions under investigation include: Trastuzumab (DRUG), Placebo (DRUG), Atezolizumab (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT04873362?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873362 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.